{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:44:47Z","timestamp":1790347487733,"version":"4.1.0"},"reference-count":79,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T00:00:00Z","timestamp":1596758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the current literature for tisagenlecleucel in the treatment of relapsed\/refractory (r\/r) B-cell acute lymphoblastic leukemia (ALL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>A literature search of PubMed (inception to June 18, 2020) and ClinicalTrials.gov was conducted using the following search terms: CTL019, chimeric antigen receptor, CAR-T, and tisagenlecleucel.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction<\/jats:title>\n                    <jats:p>All trials evaluating the use of tisagenlecleucel in B-cell ALL were reviewed and considered for inclusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis<\/jats:title>\n                    <jats:p>Tisagenlecleucel displayed overall remission rates ranging from 69% to 93% in patients who historically respond extremely poorly to salvage therapy. Remissions were durable, with 12-month relapse-free survival (RFS) rates of 55% to 59%. These promising results are tempered by the unique adverse effect profile of chimeric antigen receptor (CAR) T-cell therapy. Potentially life-threatening cytokine release syndrome (CRS) occurred in 77% to 100% of patients, and immune effector cell\u2013associated neurotoxicity syndrome (ICANS) developed in 31% to 45% of patients receiving tisagenlecleucel.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice<\/jats:title>\n                    <jats:p>The successful utilization of tisagenlecleucel therapy requires meticulous planning, prudent patient selection, multidisciplinary collaboration, and expert training to ensure optimal patient care. The complex interplay of patient- and treatment-related factors creates problematic barriers that must be expertly navigated by the health care team and authorized treatment center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>As the first US Food and Drug Administration\u2013approved gene therapy, tisagenlecleucel heralds an immunotherapeutic breakthrough for treating pediatric and young adult patients with r\/r B-cell ALL. Many questions surrounding patient-specific gene and cellular therapies remain, but their transformative potential in cancer care remains promising.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1060028020948165","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T05:55:07Z","timestamp":1596779707000},"page":"466-479","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Tisagenlecleucel in Acute Lymphoblastic Leukemia: A Review of the Literature and Practical Considerations"],"prefix":"10.1177","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7032-0398","authenticated-orcid":false,"given":"Zachery","family":"Halford","sequence":"first","affiliation":[{"name":"Union University College of Pharmacy, Jackson, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Kate","family":"Anderson","sequence":"additional","affiliation":[{"name":"Union University College of Pharmacy, Jackson, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lunawati L.","family":"Bennett","sequence":"additional","affiliation":[{"name":"Union University College of Pharmacy, Jackson, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Moody","sequence":"additional","affiliation":[{"name":"ProMedica Toledo Hospital\/Russell J. Ebeid Children\u2019s Hospital, Toledo, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,8,7]]},"reference":[{"key":"bibr1-1060028020948165","doi-asserted-by":"publisher","DOI":"10.4065\/80.11.1517"},{"key":"bibr2-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0164-6"},{"key":"bibr3-1060028020948165","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S138765"},{"key":"bibr4-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.251"},{"key":"bibr5-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-265884"},{"key":"bibr6-1060028020948165","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21219"},{"key":"bibr7-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085554"},{"key":"bibr8-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09095.x"},{"key":"bibr9-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.1983"},{"key":"bibr10-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.10.018"},{"key":"bibr11-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-4942"},{"key":"bibr12-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277"},{"key":"bibr13-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3301"},{"key":"bibr14-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3301."},{"key":"bibr15-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.8554"},{"key":"bibr16-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.2309"},{"key":"bibr17-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2019.12.004"},{"key":"bibr18-1060028020948165","unstructured":"Fala L. Kymriah (tisagenlecleucel) for young patients with acute lymphoblastic leukemia: first FDA-approved gene therapy. Accessed July 24, 2020. http:\/\/jhoponline.com\/components\/com_mams\/dl.php?dlid=138"},{"key":"bibr19-1060028020948165","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00135"},{"key":"bibr20-1060028020948165","first-page":"273","volume":"5","author":"Ehrlich P.","year":"1909","journal-title":"Ned Tijdschr Geneeskd"},{"key":"bibr21-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4402274"},{"key":"bibr22-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1126\/science.1129139"},{"key":"bibr23-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1568-1"},{"key":"bibr24-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0758"},{"key":"bibr25-1060028020948165","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00888"},{"key":"bibr26-1060028020948165","unstructured":"Yescarta. Package insert. Kite Pharma Inc; 2019."},{"key":"bibr27-1060028020948165","unstructured":"Kymriah. Package insert. Novartis Pharmaceutical Corporation; 2018."},{"key":"bibr28-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-034629"},{"key":"bibr29-1060028020948165","doi-asserted-by":"publisher","DOI":"10.3109\/10428199509059636"},{"key":"bibr30-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1186\/2162-3619-1-36."},{"key":"bibr31-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-786129"},{"key":"bibr32-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"bibr33-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"bibr34-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.3011"},{"key":"bibr35-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.2801.2801"},{"key":"bibr36-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112599"},{"key":"bibr37-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1706169"},{"key":"bibr38-1060028020948165","volume-title":"Common Terminology Criteria for Adverse Events","author":"US Department of Health and Human Services, National Institutes of Health","year":"2010"},{"key":"bibr39-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"bibr40-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"bibr41-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.11.002"},{"key":"bibr42-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000002053"},{"key":"bibr43-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"bibr44-1060028020948165","unstructured":"Actemra. Package insert. Genentech; 2017."},{"key":"bibr45-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0075-2"},{"key":"bibr46-1060028020948165","unstructured":"Sylvant. Package insert. Jenssen Biotech Inc; 2018."},{"key":"bibr47-1060028020948165","unstructured":"Kevzara. Package insert. Sanofi; 2017."},{"key":"bibr48-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2595"},{"key":"bibr49-1060028020948165","first-page":"802","volume":"14","author":"Davila ML","year":"2016","journal-title":"Clin Adv Hematol Oncol"},{"key":"bibr50-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"bibr51-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2016.03.005"},{"key":"bibr52-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.09.024"},{"key":"bibr53-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-155846"},{"key":"bibr54-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1400972"},{"key":"bibr55-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4"},{"key":"bibr56-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0041-7"},{"key":"bibr57-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-881722"},{"key":"bibr58-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-399287"},{"key":"bibr59-1060028020948165","first-page":"943","volume":"15","author":"Moussalem M","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"bibr60-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.156"},{"key":"bibr61-1060028020948165","first-page":"366","volume":"10","author":"Broder MS","year":"2017","journal-title":"Am Health Drug Benefits"},{"key":"bibr62-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01691"},{"key":"bibr63-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq495"},{"key":"bibr64-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy193"},{"key":"bibr65-1060028020948165","unstructured":"JCP Editors. CMS hospital IPPS proposed rule includes CAR-T reimbursement updates. J Clin Pathways. Published May 13, 2020. Accessed May 14, 2020. https:\/\/www.journalofclinicalpathways.com\/news\/cms-hospital-ipps-proposed-rule-includes-car-t-reimbursement-updates"},{"key":"bibr66-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-019-00090-z."},{"key":"bibr67-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1084\/jem.178.1.361"},{"key":"bibr68-1060028020948165","first-page":"3369","volume":"55","author":"Hwu P","year":"1995","journal-title":"Cancer Res"},{"key":"bibr69-1060028020948165","unstructured":"Roberts MR. Chimeric receptor molecules for delivery of co-stimulatory signals. US19950383749. Accessed July 21, 2020. https:\/\/patents.google.com\/patent\/US5686281A\/en"},{"key":"bibr70-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2004.12.003"},{"key":"bibr71-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403302"},{"key":"bibr72-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0674"},{"key":"bibr73-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1126\/science.1076514"},{"key":"bibr74-1060028020948165","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.7.4910"},{"key":"bibr75-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849"},{"key":"bibr76-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"key":"bibr77-1060028020948165","unstructured":"Food and Drug Administration. FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome. Accessed April 27, 2020. https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm574154.htm"},{"key":"bibr78-1060028020948165","unstructured":"Food and Drug Administration. FDA approves tisagenlecleucel for adults with relapsed or refractory large B-cell lymphoma. Accessed April 27, 2020. https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm606540.htm"},{"key":"bibr79-1060028020948165","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25315"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020948165","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028020948165","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020948165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:15:48Z","timestamp":1777374948000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028020948165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,7]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1177\/1060028020948165"],"URL":"https:\/\/doi.org\/10.1177\/1060028020948165","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,7]]}}}